Tag

HIV testing

Jun 30
0
Fenway Health and AIDS Action Committee have joined the #StayWoke Get Tested HIV testing campaign.

New Campaign Urges All to #StayWoke, Get Tested

By | Fenway Health Newsroom, HIV/AIDS, LGBT Health | No Comments
While the number of new HIV/AIDS cases in America has been drastically reduced since the disease’s onslaught in the 1980s, new infections are still common in a number of historically underserved groups, including young people and LGBT people of color. In an effort to address such disparities, Fenway Health and the AIDS Action Committee have partnered with the Multicultural AIDS Coalition (MAC) to launch the #StayWoke Get Tested campaign, an HIV/STI testing call to action to encourage greater testing across Massachusetts. This campaign of yourhealthboston.org is part of a statewide effort among AIDS advocacy organizations to “get to zero” – 
Read More
Apr 24
0
Fenway's location at 16 Haviland Street provides sexual health navigation and HIV/STI testing.

16 Haviland Street Offers Comprehensive Sexual Health Navigation, Testing

By | Fenway Health Newsroom, Health Care, HIV/AIDS, LGBT Health | No Comments
Are you looking for a confidential, judgment-free zone to get tested and find answers to all your sexual health questions? Fenway Health’s location at 16 Haviland Street offers full sexual health navigation and HIV/STI testing five days a week! Walk-in HIV testing at 16 Haviland, including rapid testing, is available Mondays from 10:00 AM to 5:30 PM, Tuesdays, Wednesdays, and Thursdays from 10:00 AM to 7:30 PM, and Fridays from 10:00 AM to 4:30 PM, excluding holidays. There is often little or no wait time, and patients are typically in and out in a half an hour. Why not use 
Read More
Nov 20
0
Is "treatment as prevention" the key to ending the AIDS epidemic?

HSPH Forum To Explore HIV/AIDS Treatment As Prevention

By | Community, Fenway Health Newsroom, HIV/AIDS | No Comments
Since the AIDS crisis began in the early 80s, the medical community has struggled to understand how best to stop – and eventually end – HIV transmission. On December 1, The Forum at the Harvard School of Public Health will present TREATMENT AS PREVENTION: Can We Treat Our Way Out of the AIDS Epidemic? as part of their Andelot Series on Current Science Controversies. The discussion will feature a number of HIV/AIDS experts, including Dr. Kenneth Mayer, Medical Research Director and Co-Chair of The Fenway Institute. With no cure or vaccine in sight, HIV/AIDS remains a devastating epidemic – particularly 
Read More
Nov 06
0
Fenway Health will host an HIV/STD Prevention and Treatment Research Update on November 17.

HIV/STD Prevention and Treatment Research Update To Highlight Medical Advances On November 17

By | AIDS 2014, Events, Fenway Health Newsroom, HIV/AIDS | No Comments
30 years after the start of the AIDS epidemic, the medical research community has made great strides in improving prevention and treatment methods – and that work continues today. On November 17, Fenway Health is proud to host an HIV/STD Prevention and Treatment Research Update. This event, which occurs at least once a year, brings together some of the leading HIV/AIDS and STD authorities to share new exciting breakthroughs and research findings with the community, as well as to outline where HIV/STD prevention and treatment is headed next. During the evening, experts in the fields of HIV and STD research 
Read More
Oct 17
0
The Fenway Institute is looking for participants for its HVTN-104 study.

New Fenway Institute Study Explores Revolutionary Method Of HIV Prevention

By | Fenway Health Newsroom, HIV/AIDS | No Comments
The Fenway Institute is excited to announce its participation in a nationwide novel HIV prevention study called HVTN-104. This study is being conducted to test a manufactured antibody to prevent HIV.  The purpose of this study is to learn about how the antibody works, how well it works, and the side effects that people may experience when administered this antibody. This study is currently enrolling HIV-negative individuals of any gender who are between 18 and 50 years of age and in good health. The study product, VRC01, has been tested in more than 25 people in clinical trials at the 
Read More